Yahoo19h
Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...
FierceBiotech1d
Sarepta pays $500M cash for rights to 'multiple potential blockbusters' from Arrowhead
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
STAT1d
Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases
Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...
Sarepta Therapeutics’ Strategic Partnership with Arrowhead Signals Strong Growth Prospects: A Buy Recommendation
Analyst Kostas Biliouris of BMO Capital reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...
Stocktwits on MSN1d
Arrowhead Pharma Stock Soars Pre-Market On $825M Sarepta Licensing Deal: Retail Activity Hits Year-High
Shares of Arrowhead Pharmaceuticals ($ARWR) surged as much as 22% in pre-market trading on Tuesday after announcing a $825 ...
Sarepta Therapeutics Receives Buy Rating from Gil Blum: Strategic Partnerships and Financial Stability Highlight Growth Potential
Gil Blum, an analyst from Needham, reiterated the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target was ...
MM&M17h
Five things for pharma marketers to know for Wednesday morning
The deal allows the Swiss company to develop cell therapies in-house. (The Wall Street Journal) Sarepta Therapeutics and ...